Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2015

01-06-2015 | Original Article

Discrimination of Normal and Esophageal Cancer Plasma Proteomes by MALDI-TOF Mass Spectrometry

Authors: John Schwacke, Timothy P. Millar, Charles E. Hammond, Arindam Saha, Brenda J. Hoffman, Joseph Romagnuolo, Elizabeth G. Hill, Adam J. Smolka

Published in: Digestive Diseases and Sciences | Issue 6/2015

Login to get access

Abstract

Background

Most patients presenting with symptoms of esophageal cancer (EC) have advanced disease. Even with resection, the cure rate is extremely low due to local recurrence and metastatic disease. Early detection and effective therapeutic intervention are essential to improve survival.

Aims

This study tested the hypothesis that the presence of EC modulates concentrations of specific plasma proteins and peptides, potentially allowing discrimination between EC and controls based on mass spectrometric analysis of the respective plasma proteomes.

Methods

Blood samples from 79 esophageal cancer patients and 40 age-matched normal subjects were processed to plasma, and protein/peptide sub-fractions were isolated using HIC8 or WAX-derivatized superparamagnetic beads. Triplicate matrix-assisted laser desorption time-of-flight mass spectra were acquired for specific plasma fractions from each subject.

Results

HIC8 and WAX-derivatized plasma eluates yielded 79 and 77 candidate features, respectively, and a Random Forest algorithm identified a subset of features whose peak intensities allowed discrimination between cancer patients and controls. Areas under the curve in receiver operating characteristic curves for HIC8 spectra were 0.88 and 0.83 for WAX spectra. The combined feature set discriminated EC from control plasma with 79 % sensitivity and 79 % specificity, with positive and negative test likelihood ratios of >14 and 0.17, respectively.

Conclusions

These data lay the foundation for the development of a clinically useful test for esophageal cancer based on statistical analysis of proteomic spectra of patient plasma samples. This approach will be validated by analysis of larger patient cohorts, development of cancer-specific classifiers, and assessment of racial origin imbalances.
Literature
1.
go back to reference Dahlberg PS, Ferrin LF, Grindle SM, et al. Gene expression profiles in esophageal adenocarcinoma. Ann Thorac Surg. 2004;77:1008–1015.CrossRefPubMed Dahlberg PS, Ferrin LF, Grindle SM, et al. Gene expression profiles in esophageal adenocarcinoma. Ann Thorac Surg. 2004;77:1008–1015.CrossRefPubMed
2.
go back to reference Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanisms of carcinogenesis and chemoprevention. Carcinogenesis. 2001;22:1119–1129.CrossRefPubMed Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanisms of carcinogenesis and chemoprevention. Carcinogenesis. 2001;22:1119–1129.CrossRefPubMed
3.
go back to reference Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol and socioeconomic status and adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst. 1997;89:1277–1284.CrossRefPubMed Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol and socioeconomic status and adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst. 1997;89:1277–1284.CrossRefPubMed
4.
go back to reference Chow WH, Blot WJ, Vaugn TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–155.CrossRefPubMed Chow WH, Blot WJ, Vaugn TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–155.CrossRefPubMed
6.
go back to reference Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA. 2002;287:1982–1986.CrossRefPubMed Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA. 2002;287:1982–1986.CrossRefPubMed
7.
go back to reference Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol. 2009;104:1356–1362.CrossRefPubMed Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol. 2009;104:1356–1362.CrossRefPubMed
8.
go back to reference Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119:333–338.CrossRefPubMed Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119:333–338.CrossRefPubMed
9.
go back to reference Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176.CrossRefPubMed Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176.CrossRefPubMed
10.
go back to reference Cameron AJ, Carpenter HA. Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol. 1997;92:586–591.PubMed Cameron AJ, Carpenter HA. Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol. 1997;92:586–591.PubMed
11.
go back to reference Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.PubMed Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.PubMed
13.
go back to reference Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619.CrossRefPubMed Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619.CrossRefPubMed
14.
go back to reference Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165:1424–1433.CrossRefPubMed Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165:1424–1433.CrossRefPubMed
15.
go back to reference Brabender J, Marjoram P, Salonga D, et al. A multigene expression panel for the molecular diagnosis of Barrett’s esophagus and Barrett’s adenocarcinoma of the esophagus. Oncogene. 2004;23:4780–4788.CrossRefPubMed Brabender J, Marjoram P, Salonga D, et al. A multigene expression panel for the molecular diagnosis of Barrett’s esophagus and Barrett’s adenocarcinoma of the esophagus. Oncogene. 2004;23:4780–4788.CrossRefPubMed
16.
go back to reference Brabender J, Marjoram P, Lord RV, et al. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett’s esophagus and patients with Barrett’s-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2005;14:2113–2117.CrossRefPubMed Brabender J, Marjoram P, Lord RV, et al. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett’s esophagus and patients with Barrett’s-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2005;14:2113–2117.CrossRefPubMed
17.
go back to reference Mitas M, Almeida JS, Mikhitarian K, et al. Accurate discrimination of Barrett’s esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res. 2005;11:2205–2214.CrossRefPubMed Mitas M, Almeida JS, Mikhitarian K, et al. Accurate discrimination of Barrett’s esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res. 2005;11:2205–2214.CrossRefPubMed
18.
go back to reference Metzger R, Schneider PM, Warnecke-Eberz U, et al. Molecular biology of esophageal cancer. Onkologie. 2004;27:200–206.CrossRefPubMed Metzger R, Schneider PM, Warnecke-Eberz U, et al. Molecular biology of esophageal cancer. Onkologie. 2004;27:200–206.CrossRefPubMed
19.
go back to reference Ling FC, Baldus SE, Khochfar J, et al. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett’s metaplasia and progression to cancer. Histopathology. 2007;50:203–209.CrossRefPubMed Ling FC, Baldus SE, Khochfar J, et al. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett’s metaplasia and progression to cancer. Histopathology. 2007;50:203–209.CrossRefPubMed
22.
go back to reference Morris JS, Coombes KR, Koomen J, et al. Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics. 2005;21:1764–1775.CrossRefPubMed Morris JS, Coombes KR, Koomen J, et al. Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics. 2005;21:1764–1775.CrossRefPubMed
24.
go back to reference Wu B, Abbott T, Fishman D, et al. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics. 2003;19:1636–1643.CrossRefPubMed Wu B, Abbott T, Fishman D, et al. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics. 2003;19:1636–1643.CrossRefPubMed
25.
go back to reference R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2006. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2006.
26.
go back to reference Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2:18–22. Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2:18–22.
27.
go back to reference Dobbin KK, Zhao Y, Simon RM. How large a training set is needed to develop a classifier for microarray data? Clin Cancer Res. 2008;14:108–114.CrossRefPubMed Dobbin KK, Zhao Y, Simon RM. How large a training set is needed to develop a classifier for microarray data? Clin Cancer Res. 2008;14:108–114.CrossRefPubMed
28.
go back to reference Munro NP, Cairns DA, Clarke P, et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer. 2006;119:2642–2650.CrossRefPubMed Munro NP, Cairns DA, Clarke P, et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer. 2006;119:2642–2650.CrossRefPubMed
29.
go back to reference Evans MJ, Livesey JH, Ellis MJ, et al. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem. 2001;34:107–112.CrossRefPubMed Evans MJ, Livesey JH, Ellis MJ, et al. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem. 2001;34:107–112.CrossRefPubMed
30.
go back to reference Findeisen P, Sismanidis D, Reidl M, et al. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 2005;12:2409–2411.CrossRef Findeisen P, Sismanidis D, Reidl M, et al. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 2005;12:2409–2411.CrossRef
31.
go back to reference Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005;5:3226–3245.CrossRefPubMed Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005;5:3226–3245.CrossRefPubMed
32.
go back to reference Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics. 2005;5:3414–3422.CrossRefPubMed Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics. 2005;5:3414–3422.CrossRefPubMed
33.
go back to reference Misek DE, Kuick R, Wang H, et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics. 2005;5:3343–3352.CrossRefPubMed Misek DE, Kuick R, Wang H, et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics. 2005;5:3343–3352.CrossRefPubMed
34.
go back to reference Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis. 2000;21:1164–1177.CrossRefPubMed Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis. 2000;21:1164–1177.CrossRefPubMed
35.
go back to reference Chapman K. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans. 2002;30:82–87.CrossRefPubMed Chapman K. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans. 2002;30:82–87.CrossRefPubMed
36.
go back to reference Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001;61:6029–6033.PubMed Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001;61:6029–6033.PubMed
37.
go back to reference Shiwa M, Nishimura Y, Wakatabe R, et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun. 2003;309:18–25.CrossRefPubMed Shiwa M, Nishimura Y, Wakatabe R, et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun. 2003;309:18–25.CrossRefPubMed
38.
go back to reference Wellmann A, Wollscheid V, Lu H, et al. Analysis of microdissected prostate tissue with ProteinChip arrays—a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med. 2002;9:341–347.PubMed Wellmann A, Wollscheid V, Lu H, et al. Analysis of microdissected prostate tissue with ProteinChip arrays—a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med. 2002;9:341–347.PubMed
39.
go back to reference Zheng W, Verlander JW, Lynch IJ, et al. Cellular distribution of the potassium channel KCNQ1 in normal mouse kidney. Am J Physiol Renal Physiol. 2007;292:F456–F466.CrossRefPubMed Zheng W, Verlander JW, Lynch IJ, et al. Cellular distribution of the potassium channel KCNQ1 in normal mouse kidney. Am J Physiol Renal Physiol. 2007;292:F456–F466.CrossRefPubMed
40.
go back to reference Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA. 2003;100:12343–12348.CrossRefPubMedCentralPubMed Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA. 2003;100:12343–12348.CrossRefPubMedCentralPubMed
41.
go back to reference Lewczuk P, Esselmann H, Groemer TW, et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer’s disease. Biol Psychiatry. 2004;55:524–530.CrossRefPubMed Lewczuk P, Esselmann H, Groemer TW, et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer’s disease. Biol Psychiatry. 2004;55:524–530.CrossRefPubMed
42.
go back to reference Li J, White N, Zhang Z, et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol. 2004;171:1782–1787.CrossRefPubMed Li J, White N, Zhang Z, et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol. 2004;171:1782–1787.CrossRefPubMed
43.
go back to reference Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577.CrossRefPubMed Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577.CrossRefPubMed
44.
go back to reference Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 2003;63:6971–6983.PubMed Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 2003;63:6971–6983.PubMed
45.
go back to reference Cheng AJ, Chen LC, Chien KY, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem. 2005;51:2236–2244.CrossRefPubMed Cheng AJ, Chen LC, Chien KY, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem. 2005;51:2236–2244.CrossRefPubMed
46.
go back to reference Elssner T, Fahr K, Peters D, et al. Magnetic bead-based sample preparation for clinical proteomic profiling studies. In: 51st Meeting American Society for Mass Spectroscopy, Orlando, FL; 2003. Elssner T, Fahr K, Peters D, et al. Magnetic bead-based sample preparation for clinical proteomic profiling studies. In: 51st Meeting American Society for Mass Spectroscopy, Orlando, FL; 2003.
47.
go back to reference Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem. 2004;76:1560–1570.CrossRefPubMed Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem. 2004;76:1560–1570.CrossRefPubMed
Metadata
Title
Discrimination of Normal and Esophageal Cancer Plasma Proteomes by MALDI-TOF Mass Spectrometry
Authors
John Schwacke
Timothy P. Millar
Charles E. Hammond
Arindam Saha
Brenda J. Hoffman
Joseph Romagnuolo
Elizabeth G. Hill
Adam J. Smolka
Publication date
01-06-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3513-8

Other articles of this Issue 6/2015

Digestive Diseases and Sciences 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.